Loss of the epithelial marker E-cadherin and acquisition of mesenchymal markers (e.g., vimentin, N-cadherin/CDH2 and fibronectin) are associated with a poor prognosis in different types of solid cancers, including prostate, bladder and breast cancers [8,9,10]. Here, CDH2 is linked to breast carcinoma.